Sugammadex as Rescue Therapy
NCT05661409 is a phase 4 interventional trial sponsored by Emory University. As of 18 Nov 2026, it is completed. It studies Placebo and Sugammadex in Neuromuscular Blockade. The registry lists an enrollment of 46 participants at 1 site in 1 country. The registry lists a start date of 21 Jul 2023 and a primary completion date of 2 Aug 2024.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT05661409 |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional trial |
| Lead sponsor | Emory University |
| Enrollment | 46 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Neuromuscular Blockade |
| Drugs | Placebo and Sugammadex |
| Start | 21 Jul 2023 |
| Primary completion | 2 Aug 2024 |
| Study completion | 2 Aug 2024 |
| Last update posted | 5 Sept 2025 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Matthew Whalin, MD
Assistant Professor
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Grady Memorial Hospital
Atlanta
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT05661409
Each answer restates registry values shown on this page.
What is NCT05661409?
NCT05661409 is a phase 4 interventional trial sponsored by Emory University. It studies Placebo and Sugammadex in Neuromuscular Blockade.
Who leads NCT05661409?
The registry names Matthew Whalin, MD (principal investigator, Assistant Professor) as the overall official.
Where does NCT05661409 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT05661409 study?
The registered drug and biological interventions are Placebo and Sugammadex.
When did NCT05661409 end?
The registry lists a primary completion date of 2 Aug 2024 and a study completion date of 2 Aug 2024. The sponsor last updated the record on 5 Sept 2025.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.